Cost-Effectiveness of Pembrolizumab (Keytruda®) Versus Ipilimumab in Patients with Advanced Melanoma in Canada
Abstract
Authors
J Wang I Chabot W El-Hadi R Xu J Pellissier I Iliopoulos
J Wang I Chabot W El-Hadi R Xu J Pellissier I Iliopoulos
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now